A Journey Through Myeloma Evolution: From the Normal Plasma Cell to Disease Complexity. Issue 6 (24th December 2020)

• Record Type: Journal Article
• Authors: Da Vià, Matteo C.; Ziccheddu, Bachisio; Maeda, Akihiro; Bagnoli, Filippo; Perrone, Giulia; Bolli, Niccolò
• Is Part Of: HemaSphere. Volume 4:Issue 6(2020)
• Page Start: e502
• Publication Date: 2020-12-24
• Subjects: Hematology -- Periodicals; 616.15005
• DOI: 10.1097/HS9.0000000000000502
• Languages: English
• ISSNs: 2572-9241

Abstract

Abstract : Abstract: The knowledge of cancer origin and the subsequent tracking of disease evolution represent unmet needs that will soon be within clinical reach. This will provide the opportunity to improve patient's stratification and to personalize treatments based on cancer biology along its life history. In this review, we focus on the molecular pathogenesis of multiple myeloma (MM), a hematologic malignancy with a well-known multi-stage disease course, where such approach can sooner translate into a clinical benefit. We describe novel insights into modes and timing of disease initiation. We dissect the biology of the preclinical and pre-malignant phases, elucidating how knowledge of the genomics of the disease and the composition of the microenvironment allow stratification of patients based on risk of disease progression. Then, we explore cell-intrinsic and cell-extrinsic drivers of MM evolution to symptomatic disease. Finally, we discuss how this may relate to the development of refractory disease after treatment. By integrating an evolutionary view of myeloma biology with the recent acquisitions on its clonal heterogeneity, we envision a way to drive the clinical management of the disease based on its detailed biological features more than surrogates of disease burden.